Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
PUMA BIOTECHNOLOGY, INC.
Bear Case (25th pct.)
-45.5% vs price
Base Case (Median)
-17.3% vs price
Bull Case (75th pct.)
2.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $8.13 | -27.8% | High (40%) |
| PE Comparable | $11.84 | 5.2% | Medium (25%) |
| Graham Number | $5.47 | -51.4% | Medium (40%) |
| EV/EBITDA | $10.49 | -6.8% | Medium (20%) |
| EV/FCF | $16.15 | 43.5% | Medium (20%) |
| Earnings Power Value | $4.80 | -57.4% | Medium (50%) |
Based on 6 out of 7 methods, PBYI appears fairly valued at the current price of $11.26. The base case fair value of $9.31 implies 17.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.